Evidence map›Paper›PMID 30823685›Full record

ArticleMolecules (Basel, Switzerland)2019

Sterile and Dual-Porous Aerogels Scaffolds Obtained through a Multistep Supercritical CO₂-Based Approach.

Víctor Santos-Rosales, Inés Ardao, Carmen Alvarez-Lorenzo, Nilza Ribeiro, Ana L Oliveira, Carlos A García-González

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 54 citations in OpenAlex.

  1. COGels (Basel, Switzerland) · 2025
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Supercritical COThe Science of the total environment · 2022
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Víctor Santos-RosalesDepartamento de Farmacología, Farmacia y Tecnología Farmacéutica, R+D Pharma group (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain. victor.santos.rosales@rai.usc.es.
Inés ArdaoBioFarma Research group, Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CiMUS), Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain. ines.ardao@usc.es.
Carmen Alvarez-LorenzoDepartamento de Farmacología, Farmacia y Tecnología Farmacéutica, R+D Pharma group (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain. carmen.alvarez.lorenzo@usc.es.ORCID 0000-0002-8546-7085
Nilza RibeiroCBQF-Centro de Biotecnologia e Química Fina-Laboratório Associado, Escola Superior de Biotecnologia, Universidade Católica Portuguesa, 4200-375 Porto, Portugal. nribeiro@porto.ucp.pt.
Ana L OliveiraCBQF-Centro de Biotecnologia e Química Fina-Laboratório Associado, Escola Superior de Biotecnologia, Universidade Católica Portuguesa, 4200-375 Porto, Portugal. aloliveira@porto.ucp.pt.
Carlos A García-GonzálezDepartamento de Farmacología, Farmacia y Tecnología Farmacéutica, R+D Pharma group (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain. carlos.garcia@usc.es.ORCID 0000-0001-9542-3679
Universidade de Santiago de Compostela · ESUniversidade Católica Portuguesa · PT

Funding

Agencia Estatal de Investigación AEIConsellería de Cultura, Educación e Ordenación Universitaria, Xunta de Galicia ED481A-2018/014European Commission FEDERFundação para a Ciência e a Tecnologia IF/00411/2013Fundação para a Ciência e a Tecnologia IF/00411/2013/CP1167Fundação para a Ciência e a Tecnologia UID/Multi/50016/2013Interreg V-A POCTEP Programme 0245_IBEROS_1_EMinisterio de Economía, Industria y Competitividad, Gobierno de España RYC2014-15239Ministerio de Economía, Industria y Competitividad, Gobierno de España SAF2017-83118-RXunta de Galicia ED431C 2016/008Xunta de Galicia ED431F 2016/010
6 · The paper itself

Abstract

Aerogels from natural polymers are endowed with attractive textural and biological properties for biomedical applications due to their high open mesoporosity, low density, and reduced toxicity. Nevertheless, the lack of macroporosity in the aerogel structure and of a sterilization method suitable for these materials restrict their use for regenerative medicine purposes and prompt the research on getting ready-to-implant dual (macro + meso)porous aerogels. In this work, zein, a family of proteins present in materials for tissue engineering, was evaluated as a sacrificial porogen to obtain macroporous starch aerogels. This approach was particularly advantageous since it could be integrated in the conventional aerogel processing method without extra leaching steps. Physicochemical, morphological, and mechanical characterization were performed to study the effect of porogen zein at various proportions (0:1, 1:2, and 1:1 zein:starch weight ratio) on the properties of the obtained starch-based aerogels. From a forward-looking perspective for its clinical application, a supercritical CO₂ sterilization treatment was implemented for these aerogels. The sterilization efficacy and the influence of the treatment on the aerogel final properties were evaluated mainly in terms of absence of microbial growth, cytocompatibility, as well as physicochemical, structural, and mechanical modifications.

Indexed as

PorosityTissue EngineeringCarbon DioxideGelsHumansPolymersProstheses and ImplantsStarchCarbon DioxideGelsPolymersStarchregenerative medicinestarch aerogelssupercritical CO2supercritical sterilizationzein

Identifiers

PMID30823685
PMCPMC6429194
OpenAlexW2915572696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.